Cellular Dynamics Licenses Technology from ViaCyte Cellular Dynamics International, Inc. announced it has strengthened its intellectual property portfolio by licensing patented definitive endoderm differentiation technology from ViaCyte, Inc., a stem cell company focused on diabetes therapy. [Cellular Dynamics International, Inc. Press Release] Aduro BioTech Licenses GVAX Pancreas from BioSante Pharmaceuticals to Develop a Therapeutic Vaccine in Conjunction with CRS-207 for Pancreatic Cancer Aduro BioTech has licensed GVAX Pancreas Cancer Vaccine (GVAX Pancreas) and GVAX Prostate Cancer Vaccine (GVAX Prostate) from BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization. [BusinessWire] TeloVac Pancreatic Cancer Vaccine Trial Launched in UK More than 1,000 patients with advanced pancreatic cancer have joined the TeloVac trial at 53 UK hospitals. [BBC News] Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency Eli Lilly and Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application for liprotamase, a non-porcine pancreatic enzyme replacement therapy, under investigation for the treatment of exocrine pancreatic insufficiency. [Eli Lilly and Company Press Release] BYDUREON™ Recommended for Approval in Europe Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of exenatide 2 mg powder and solvent for prolonged release suspension for injection (proposed trade name BYDUREON™) in the European Union for the treatment of type 2 diabetes in combination with certain oral therapies. [Eli Lilly and Company Press Release] Lixisenatide Significantly Reduces HbA1c Without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas Sanofi-aventis announced that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from baseline versus placebo. [Sanofi-aventis Press Release] Halozyme’s Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps Halozyme Therapeutics, Inc. announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme’s rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog®, accelerates insulin absorption and shortened its duration of action. [Halozyme Therapeutics, Inc. Press Release] American College of Endocrinology (ACE) and Lilly Diabetes Offer Free Checklist to Help People With Diabetes Prepare Before Disaster Strikes The American College of Endocrinology and Lilly Diabetes created the “Power of Prevention®: Diabetes Disaster Plan,” a comprehensive checklist of items for people with diabetes to use in order to prepare for a potential disaster. [Eli Lilly and Company Press Release] Several Cancers Underrepresented in Clinical Trials Several cancers with a high burden of disease are not receiving the clinical trial investment they require, according to a University of Sydney study. [University of Sydney Press Release] |